BACKGROUND AND PURPOSE: Limited data suggest that intracerebral hemorrhage related to oral anticoagulant therapy (OAT ICH) is associated with more hemorrhage expansion and a worse prognosis than spontaneous ICH (SICH). METHODS: We examined patients enrolled in the placebo arm of the CHANT study, a prospective randomized trial of a putative neuroprotectant in patients with ICH. All patients had neuroimaging within 6 hours of symptom onset and at 72 hours. Initial ICH volume and hemorrhage expansion were determined by a central reader. Multivariable logistic regression was used to determine factors associated with ICH expansion and mortality at 90 days. RESULTS: Of 303 patients included, 21 (6.9%) had OAT ICH. Baseline median ICH volume was greater in patients with OAT ICH compared to SICH (30.6 versus 14.4 mL, P=0.03). Hemorrhage expansion (defined as >33% increase in ICH volume) occurred in 56% of patients with OAT ICH compared to 26% of SICH (P=0.006). Mortality was substantially higher in OAT ICH (62% versus 17%, P<0.001). In multivariable analysis, time to neuroimaging and oral anticoagulant use were independently associated with hemorrhage expansion, and age, gender, and oral anticoagulant use were independently associated with mortality. CONCLUSIONS: These findings confirm that OAT ICH is associated with more hemorrhage expansion and greater mortality than SICH.
RCT Entities:
BACKGROUND AND PURPOSE: Limited data suggest that intracerebral hemorrhage related to oral anticoagulant therapy (OAT ICH) is associated with more hemorrhage expansion and a worse prognosis than spontaneous ICH (SICH). METHODS: We examined patients enrolled in the placebo arm of the CHANT study, a prospective randomized trial of a putative neuroprotectant in patients with ICH. All patients had neuroimaging within 6 hours of symptom onset and at 72 hours. Initial ICH volume and hemorrhage expansion were determined by a central reader. Multivariable logistic regression was used to determine factors associated with ICH expansion and mortality at 90 days. RESULTS: Of 303 patients included, 21 (6.9%) had OAT ICH. Baseline median ICH volume was greater in patients with OAT ICH compared to SICH (30.6 versus 14.4 mL, P=0.03). Hemorrhage expansion (defined as >33% increase in ICH volume) occurred in 56% of patients with OAT ICH compared to 26% of SICH (P=0.006). Mortality was substantially higher in OAT ICH (62% versus 17%, P<0.001). In multivariable analysis, time to neuroimaging and oral anticoagulant use were independently associated with hemorrhage expansion, and age, gender, and oral anticoagulant use were independently associated with mortality. CONCLUSIONS: These findings confirm that OAT ICH is associated with more hemorrhage expansion and greater mortality than SICH.
Authors: H Bart Brouwers; Alessandro Biffi; Alison M Ayres; Kristin Schwab; Lynelle Cortellini; Javier M Romero; Natalia S Rost; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: Stroke Date: 2012-04-24 Impact factor: 7.914
Authors: Santiago R Leal-Noval; Manuel Muñoz; Marisol Asuero; Enric Contreras; José A García-Erce; Juan V Llau; Victoria Moral; José A Páramo; Manuel Quintana Journal: Blood Transfus Date: 2013-06-17 Impact factor: 3.443
Authors: Wesley R Zemrak; Kathryn E Smith; Stephen S Rolfe; Teresa May; Robert L Trowbridge; Timothy L Hayes; Gene A Grindlinger; David B Seder Journal: Neurocrit Care Date: 2017-12 Impact factor: 3.210
Authors: Matthew L Flaherty; Opeolu Adeoye; Padmini Sekar; Mary Haverbusch; Charles J Moomaw; Haiyang Tao; Joseph P Broderick; Daniel Woo Journal: Stroke Date: 2009-03-12 Impact factor: 7.914
Authors: Taku Inohara; Ying Xian; Li Liang; Roland A Matsouaka; Jeffrey L Saver; Eric E Smith; Lee H Schwamm; Mathew J Reeves; Adrian F Hernandez; Deepak L Bhatt; Eric D Peterson; Gregg C Fonarow Journal: JAMA Date: 2018-02-06 Impact factor: 56.272